01.13.12
Molecular Profiles has begun construction of a new manufacturing facility at its site in Nottingham, investing $13.8 million to expand its current manufacturing capabilities. The expansion covers all services including formulation development, polymorph and salt selection, analytical services, materials characterization and clinical trial manufacturing.
The new GMP facility, planned to open in late 2012, will provide an additional 30,000 sq. ft. of space, including six new GMP suites, new labs and a clinical packing suite. The facility will have capabilities to manufacture highly potent compounds up to OEB 4 level, as well as handle dosage forms including solids, liquids, semi-solids and inhaled products. The expansion allows the company to cover Phase I and II trial requirements with manufacturing batch scale of 30kg.
Nikin Patel, chief executive officer of Molecular Profiles, said, “The construction of significantly larger manufacturing and laboratory facilities is a strategic decision based on customer demand. Our strategy for expansion is well underway and securing the regional growth funding is a clear endorsement of our strategic growth plans. Following our double win of the Queen’s Award in 2007 and 2011 in the category of innovation, we have once again affirmed our ambition and continuous development.”
The new GMP facility, planned to open in late 2012, will provide an additional 30,000 sq. ft. of space, including six new GMP suites, new labs and a clinical packing suite. The facility will have capabilities to manufacture highly potent compounds up to OEB 4 level, as well as handle dosage forms including solids, liquids, semi-solids and inhaled products. The expansion allows the company to cover Phase I and II trial requirements with manufacturing batch scale of 30kg.
Nikin Patel, chief executive officer of Molecular Profiles, said, “The construction of significantly larger manufacturing and laboratory facilities is a strategic decision based on customer demand. Our strategy for expansion is well underway and securing the regional growth funding is a clear endorsement of our strategic growth plans. Following our double win of the Queen’s Award in 2007 and 2011 in the category of innovation, we have once again affirmed our ambition and continuous development.”